Role of TLR4 polymorphisms and gut–brain axis signaling in the therapeutic response to natalizumab in multiple sclerosis

Vol. 1 2024 - 346164
E-poster
Favoritar este trabalho
Como citar esse trabalho?
Resumo

Introduction: Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system, characterized by demyelinating lesions caused by autoreactive lymphocytes that cross the blood-brain barrier (BBB) and promote neuroinflammation. Gut microbiota dysbiosis has been implicated in MS pathophysiology via gut-brain axis signaling. Lipopolysaccharide (LPS), a bacterial product from gram-negative microbiota, activates Toll-like receptor 4 (TLR4), promoting inflammatory responses linked to BBB dysfunction and neuroinflammation. Natalizumab (NTZ), a monoclonal antibody that blocks immune cell migration across the BBB, is highly effective, but approximately 25% of patients show inadequate response. Genetic variation in TLR4 may contribute to this interindividual variability. Objectives: To investigate the contribution of TLR4 genetic variants and TLR4-mediated inflammatory signaling to the therapeutic response to natalizumab in multiple sclerosis. Methods: We enrolled 139 NTZ-treated patients from HUPE-UERJ and HUCFF-UFRJ. Peripheral blood was collected for DNA extraction and SNP genotyping (rs10759931, rs2737190). PBMCs from genotyped healthy individuals were isolated, stimulated with LPS for 24h, and TLR4 expression was evaluated by qPCR. An EAE model is being standardized to further investigate TLR4 signaling and gut-brain axis mechanisms in NTZ response. Results: The polymorphic AA genotype of rs10759931 and rs2737190 was associated with better NTZ response, while the wild-type GG genotype prevailed among non-responders. In the functional assay, the GG genotype of rs10759931 was associated with higher TLR4 expression after LPS stimulation. Conclusion: TLR4 polymorphisms may influence NTZ efficacy in MS by modulating inflammatory signaling, supporting the relevance of pharmacogenetic mechanisms for personalized medicine strategies in MS. Financial Support: FAPERJ and CNPq. CAAE: 64171122.7.0000.5259/69411517.2.0000.5258. CEUA: 029/2025.

Compartilhe suas ideias ou dúvidas com os autores!

Sabia que o maior estímulo no desenvolvimento científico e cultural é a curiosidade? Deixe seus questionamentos ou sugestões para o autor!

Faça login para interagir

Tem uma dúvida ou sugestão? Compartilhe seu feedback com os autores!

Instituições
  • 1 Rio de Janeiro State University
  • 2 Colégio Pedro ii-Campus Niterói
  • 3 Universidade Federal de Juiz de Fora
  • 4 Universidade do Estado do Rio de Janeiro
Eixo Temático
  • Neuroinflammation
Palavras-chave
Multiple Sclerosis
Pharmacogenetics
Natalizumab
Gut-brain Axis